title: Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement.
abstract: Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme that plays a critical role in diverse cellular functions, such as DNA damage detection and repair, transcriptional regulation and cell death. Furthermore, PARP-1 has emerged as a key player in the pathogenesis of multiple inflammatory diseases and has become a promising target for the treatment of cardiovascular disorders, neurodegenerative diseases and cancer. An increasing body of evidence has linked alterations in the expression levels of PARP-1, enzymatic activity and presence of polymorphism to gastrointestinal malignancies, including oesophageal, gastric, pancreas, liver and colorectal cancers. PARP inhibition has been proposed as a valuable strategy for treating these gastrointestinal disorders. This paper summarises the most significant current literature on the involvement of PARP-1 in gastrointestinal cancer, focusing in particular on its role in the development and occurrence of tumours, providing information about clinical trials and exploring therapeutic possibilities.
authors.affiliation: Biomedical Research Institute of Granada (ibs.GRANADA), Granada. Spain.
authors.forename: Sandra M
authors.initials: SM
authors.lastname: Martín-Guerrero
authors.affiliation: Biomedical Research Institute of Granada (ibs.GRANADA), Granada. Spain.
authors.forename: Josefa
authors.initials: J
authors.lastname: León
authors.affiliation: Biomedical Research Institute of Granada (ibs.GRANADA), Granada. Spain.
authors.forename: Rosa
authors.initials: R
authors.lastname: Quiles-Perez
authors.affiliation: Doctoral programme in Regenerative Medicine, Granada University, Granada. Spain.
authors.forename: Laura
authors.initials: L
authors.lastname: Belmonte
authors.affiliation: Biomedical Research Institute of Granada (ibs.GRANADA), Granada. Spain.
authors.forename: David
authors.initials: D
authors.lastname: Martin-Oliva
authors.affiliation: Biomedical Research Institute of Granada (ibs.GRANADA), Granada. Spain.
authors.forename: Ángeles
authors.initials: Á
authors.lastname: Ruiz-Extremera
authors.affiliation: Biomedical Research Institute of Granada (ibs.GRANADA), Granada. Spain.
authors.forename: Javier
authors.initials: J
authors.lastname: Salmerón
authors.affiliation: Laboratory of Medical Research, Clinical Management Unit of Digestive Disease, San Cecilio University Hospital, Avda de Madrid s/n, 18012, Granada. Spain.
authors.forename: José Antonio
authors.initials: JA
authors.lastname: Muñoz-Gámez
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D055808:Drug Discovery; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D041981:Gastrointestinal Tract / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D058990:Molecular Targeted Therapy; D000071137:Poly (ADP-Ribose) Polymerase-1 / Q000032:analysis / Q000037:antagonists & inhibitors / Q000235:genetics*; D000067856:Poly(ADP-ribose) Polymerase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D020641:Polymorphism, Single Nucleotide
chemical_list: D000970:Antineoplastic Agents; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D000071137:Poly (ADP-Ribose) Polymerase-1
keywords: Biomarker; PARP inhibitors; carcinogenesis; gastrointestinal cancer; poly (ADP-ribose) polymerase-1
  (PARP-1); synthetic lethality